• Medicine
• Published in Annales d'endocrinologie 2013
• DOI:10.1016/j.ando.2013.04.004

Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.

@article{Kerlan2013UseOI,
  title={Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.},
  author={V{\'e}ronique Kerlan and Didier Gouet and Michel Marre and {\'E}ric Renard},
  journal={Annales d'endocrinologie},
  year={2013},
  volume={74 5-6},
  pages={
          487-90
        }
}

• Véronique Kerlan, Didier Gouet, +1 author Éric Renard

Insulin degludec is a new basal insulin analogue with an ultra-long duration of action that provides a flat and stable action profile with a duration of action greater than 42 hours. Two clinical trials comparing insulin degludec and insulin glargine in basal-bolus therapy have recently been published. Both were 52-week, multicentre, randomised (3:1), treat-to-target trials in patients already using insulin. In both type 1 (n=629) and type 2 diabetes (n=1006), insulin degludec was non-inferior… CONTINUE READING

View on PubMed

Alternate Sources

Save to Library

Create Alert

Cite